Tenax Therapeutics (TENX) Goodwill & Intangibles (2011 - 2017)
Tenax Therapeutics (TENX) posted quarterly Goodwill & Intangibles of $22.0 million for Q3 2017, down 33.86% year-over-year from $33.3 million in Q3 2016, and little changed on a QoQ basis from $22.0 million in Q2 2017.
Tenax Therapeutics (TENX) Goodwill & Intangibles (2011 - 2017) Analysis & Trends
Tenax Therapeutics has reported Goodwill & Intangibles for 7 years, with the latest figure at $22.0 million in Q3 2017.
- Goodwill & Intangibles for Q3 2017 came in at $22.0 million, down 33.86% year-over-year; the trailing twelve-month figure through Sep 2017 was $22.0 million (down 33.86% YoY), and the FY2016 annual result was $22.0 million, down 33.86% from the prior year.
- Goodwill & Intangibles was little changed at $22.0 million in Q3 2017, from $22.0 million in the prior quarter.
- Over five years, Goodwill & Intangibles peaked at $33.3 million in Q4 2015 and troughed at $893358.0 in Q2 2014.
- A 5-year average of $19.5 million and a median of $22.0 million in 2016 frame the typical range for Goodwill & Intangibles.
- The widest annual swing landed in 2015, when Goodwill & Intangibles jumped 2535.43%; it then slumped 33.86% in 2016.
- A 5-year view of Goodwill & Intangibles shows it stood at $924698.0 in 2013, then dropped by 3.39% to $893358.0 in 2014, then surged by 3623.6% to $33.3 million in 2015, then slumped by 33.86% to $22.0 million in 2016, then changed by 0.0% to $22.0 million in 2017.
- Per Business Quant data, the three most recent Goodwill & Intangibles figures were $22.0 million in Q3 2017, $22.0 million in Q2 2017, and $22.0 million in Q1 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Tenax Therapeutics | 78.47 Mn | 78.47 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2017 | 22.00 Mn |
| Jun 30, 2017 | 22.00 Mn |
| Sep 30, 2016 | 33.27 Mn |
| Jun 30, 2016 | 33.27 Mn |
| Dec 31, 2015 | 11.27 Mn |
| Apr 30, 2015 | 23.54 Mn |
| Apr 30, 2014 | 893,358.00 |
| Apr 30, 2013 | 924,698.00 |
| Jan 31, 2013 | 923,397.00 |
| Oct 31, 2012 | 904,498.00 |
| Jul 31, 2012 | 881,317.00 |
| Apr 30, 2012 | 872,971.00 |
| Jan 31, 2012 | 863,510.00 |
| Oct 31, 2011 | 831,407.00 |
| Jul 31, 2011 | 746,033.00 |
| Apr 30, 2011 | 699,951.00 |